葡萄牙使用阿扎胞苷治疗的急性髓系白血病患者的临床结局：一项回顾性多中心研究。
Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study.
作者信息
Almeida António, Ferreira Ana Rita, Costa Maria João, Silva Sofia, Alnajjar Khalil, Bogalho Isabel, Pierdomenico Francesca, Esteves Susana, Alpoim Mafalda, Braz Gil, Cortesão Emilia, Pinto Ricardo
机构信息
Serviço de Hematologia, Instituto Português de Oncologia de Lisboa, Francisco Gentil, Lisbon, Portugal.
Serviço de Hematologia, Centro Hospitalar Lisboa Norte, Hospital Santa Maria, Lisboa, Portugal.
出版信息
Leuk Res Rep. 2016 Dec 23;7:6-10. doi: 10.1016/j.lrr.2016.12.002. eCollection 2017.
Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104). These results support the efficacy of AZA in AML in the elderly in any line of treatment.
从4家葡萄牙医院收集了77例接受阿扎胞苷（AZA）治疗的老年急性髓系白血病（AML）患者以及50例接受强化化疗（IC）的老年AML患者的回顾性数据。接受AZA作为一线治疗的患者中位总生存期为10.6个月。缓解情况（总缓解率44%）对总生存期有显著影响（p<0.0001）。对照IC队列的中位总生存期显著低于一线接受AZA治疗的队列（p=0.0104）。这些结果支持了AZA在老年AML患者任何治疗线中的疗效。
Zotero 插件